4/17
12:38 pm
tsvt
2seventy bio (TSVT) Rises More Than 50% in 3 Months: Here's Why [Yahoo! Finance]
Low
Report
2seventy bio (TSVT) Rises More Than 50% in 3 Months: Here's Why [Yahoo! Finance]
4/8
07:10 pm
tsvt
2seventy bio, Inc. (NASDAQ: TSVT) had its price target raised by analysts at Citigroup Inc. from $9.00 to $12.00. They now have a "buy" rating on the stock.
Low
Report
2seventy bio, Inc. (NASDAQ: TSVT) had its price target raised by analysts at Citigroup Inc. from $9.00 to $12.00. They now have a "buy" rating on the stock.
4/5
09:09 am
tsvt
U.S. FDA Approves Bristol Myers Squibb and 2seventy bio's Abecma for Triple-Class Exposed Relapsed or Refractory Multiple Myeloma After Two Prior Lines of Therapy [Yahoo! Finance]
High
Report
U.S. FDA Approves Bristol Myers Squibb and 2seventy bio's Abecma for Triple-Class Exposed Relapsed or Refractory Multiple Myeloma After Two Prior Lines of Therapy [Yahoo! Finance]
4/1
07:30 am
tsvt
2seventy bio Announces Completion of Oncology and Autoimmune Pipeline Divestiture to Regeneron
Medium
Report
2seventy bio Announces Completion of Oncology and Autoimmune Pipeline Divestiture to Regeneron
3/20
05:10 pm
tsvt
2seventy bio Announces Appointments of Eli Casdin and Charles Newton to Board of Directors [Yahoo! Finance]
Medium
Report
2seventy bio Announces Appointments of Eli Casdin and Charles Newton to Board of Directors [Yahoo! Finance]
3/20
05:04 pm
tsvt
2seventy bio Announces Appointments of Eli Casdin and Charles Newton to Board of Directors
Medium
Report
2seventy bio Announces Appointments of Eli Casdin and Charles Newton to Board of Directors
3/18
02:51 pm
tsvt
2seventy bio, Inc. (NASDAQ: TSVT) had its "neutral" rating re-affirmed by analysts at Wedbush. They now have a $5.00 price target on the stock.
Low
Report
2seventy bio, Inc. (NASDAQ: TSVT) had its "neutral" rating re-affirmed by analysts at Wedbush. They now have a $5.00 price target on the stock.
3/15
06:42 pm
tsvt
FDA Advisory Committee Votes in Favor of Bristol Myers Squibb's and 2seventy bio's Abecma for Triple-Class Exposed Multiple Myeloma in Earlier Lines of Therapy [Yahoo! Finance]
Medium
Report
FDA Advisory Committee Votes in Favor of Bristol Myers Squibb's and 2seventy bio's Abecma for Triple-Class Exposed Multiple Myeloma in Earlier Lines of Therapy [Yahoo! Finance]
3/6
06:27 am
tsvt
When Will 2seventy bio, Inc. (NASDAQ:TSVT) Turn A Profit? [Yahoo! Finance]
Medium
Report
When Will 2seventy bio, Inc. (NASDAQ:TSVT) Turn A Profit? [Yahoo! Finance]
3/5
07:44 am
tsvt
2seventy bio Inc (TSVT) Reports Mixed Financial Results Amid Strategic Shift and Competitive ... [Yahoo! Finance]
Medium
Report
2seventy bio Inc (TSVT) Reports Mixed Financial Results Amid Strategic Shift and Competitive ... [Yahoo! Finance]
3/5
07:18 am
tsvt
2seventy bio Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Operational Progress [Yahoo! Finance]
Medium
Report
2seventy bio Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Operational Progress [Yahoo! Finance]
3/5
07:00 am
tsvt
2seventy bio Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Operational Progress
Medium
Report
2seventy bio Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Operational Progress
3/4
10:51 am
tsvt
Should You Buy 2seventy bio (TSVT) Ahead of Earnings? [Yahoo! Finance]
Medium
Report
Should You Buy 2seventy bio (TSVT) Ahead of Earnings? [Yahoo! Finance]
3/1
07:07 am
tsvt
2seventy bio to Report Fourth Quarter and Full Year 2023 Financial Results and Participate in Upcoming Investor Conferences [Yahoo! Finance]
Medium
Report
2seventy bio to Report Fourth Quarter and Full Year 2023 Financial Results and Participate in Upcoming Investor Conferences [Yahoo! Finance]
3/1
07:00 am
tsvt
2seventy bio to Report Fourth Quarter and Full Year 2023 Financial Results and Participate in Upcoming Investor Conferences
Medium
Report
2seventy bio to Report Fourth Quarter and Full Year 2023 Financial Results and Participate in Upcoming Investor Conferences
2/5
04:05 pm
tsvt
2seventy bio to Participate in Upcoming Investor Conferences
Low
Report
2seventy bio to Participate in Upcoming Investor Conferences
2/1
10:10 am
tsvt
2seventy bio, Inc. (TSVT) Surges 28.2%: Is This an Indication of Further Gains? [Yahoo! Finance]
Low
Report
2seventy bio, Inc. (TSVT) Surges 28.2%: Is This an Indication of Further Gains? [Yahoo! Finance]
2/1
05:57 am
tsvt
2seventy bio, Inc. (NASDAQ: TSVT) was upgraded by analysts at Leerink Partnrs from a "market perform" rating to an "outperform" rating.
Low
Report
2seventy bio, Inc. (NASDAQ: TSVT) was upgraded by analysts at Leerink Partnrs from a "market perform" rating to an "outperform" rating.
1/31
08:07 am
tsvt
2seventy bio, Inc. (NASDAQ: TSVT) had its "market perform" rating re-affirmed by analysts at TD Cowen.
High
Report
2seventy bio, Inc. (NASDAQ: TSVT) had its "market perform" rating re-affirmed by analysts at TD Cowen.
1/31
07:29 am
tsvt
2seventy bio, Inc. (NASDAQ: TSVT) was upgraded by analysts at SVB Leerink LLC from a "market perform" rating to an "outperform" rating. They now have a $18.00 price target on the stock, up previously from $5.00.
High
Report
2seventy bio, Inc. (NASDAQ: TSVT) was upgraded by analysts at SVB Leerink LLC from a "market perform" rating to an "outperform" rating. They now have a $18.00 price target on the stock, up previously from $5.00.
1/30
07:01 am
tsvt
2seventy bio Announces New Strategic Path Forward
High
Report
2seventy bio Announces New Strategic Path Forward
1/25
07:11 pm
tsvt
CAR T-Cell Therapy Market to Reach $35.9 Billion by 2032 At A 28.5% CAGR: Allied Market Research [Yahoo! Finance]
Medium
Report
CAR T-Cell Therapy Market to Reach $35.9 Billion by 2032 At A 28.5% CAGR: Allied Market Research [Yahoo! Finance]